Abstracts of the 2022 Annual Meeting of the ALEH
More infoHepatitis C virus is the leading cause of end-stage liver disease worldwide. Assessing the severity of liver disease is necessary before the start of therapy since this will depend on the regimen and subsequent prognosis, so there are invasive and non-invasive measures documenting advanced liver fibrosis and cirrhosis are related to worse results; at the time of diagnosis, more than 50% have evidence of cirrhosis, so it is necessary to evaluate the follow-up of patients with advanced liver disease and document its regression non-invasively due to sustained virological response. This study aimed to determine with non-invasive methods the regression of fibrosis in sustained virological responders in the Infectious Disease Unit and to document which stage is predominant when presenting sustained virological response.
Materials and MethodsObservational, retrospective, longitudinal study, elastography was performed, FIB4 and APRI were calculated before and after the sustained virological response. The regression was analyzed with McNemar's Chi square to document differences before and after treatment.
Results53 patients were acquired, and of these, 51% were women; the three non-invasive methods were represented in tables before and after, being F2 in the three methods the main degree of fibrosis before treatment and when they had sustained virological response this was found to F0 and F1, p <0.001 when comparing before and after treatment in the three non-invasive methods.
ConclusionsThere is regression now of having sustained virological response in patients who presented advanced disease documented with non-invasive methods. The stages in order of frequency according to APRI after treatment are F0 with 72%, FIB 4 with 51% stage F0 and for elastography, it is F0 with 26% and F1 with 44%.